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Background: A survey was conducted to evaluate whether a steady improvement in the quality of life of
Rheumatoid Arthritis (RA) patients as frequently reported in clinical studies, does actually occur. The focus of this
study laid on the personal perception of RA patients. How do patients who have been treated along accepted
guidelines see the state of their health and their joint pain at different points in time?
Methods: RA patients were asked to complete a questionnaire and return it to an opinion research centre. The
questionnaire, which was developed by the authors, was divided into the areas: demography, symptom description
and medical care, as well as the illness in a personal context. Three telephone interviews followed in monthly
intervals when the patients´ feelings about their illness, their every-day coping mechanisms and their social lives
were rated. Intra-subject correlation and the level of agreement among patients when assessed at three different
points within a two month period, was determined.
Results: 127 patients replied to the questionnaire. RA exerts a significant impact on a patient’s daily life. Average
ratings of current state of health and joint pain (answered on a 5-part scale extending from 1 (very good) to 5
(very bad)) range between 2.6 and 2.9 all three times. However, intra-subject correlation between the different
assessment times, is in general quite modest. Concerning the question: “How is your join pain today?” only 14 of
127 participants express identical ratings all three times , while in one third of the participants, a difference of two
digits on the 5-part scale, at least twice had to be noticed. Intra-class correlation coefficients between answers at
different points are often much smaller than 0.5. Results were similar in all subgroups analysed (men vs. women;
patients receiving biologics vs. those not receiving biologics; disease duration ≤3 years vs. 4 to 10 years vs. ≥11 years).
Conclusion: On an individual level personal assessments of health, well-being and joint pain are nevertheless unsteady
even within the timeframe of two months. This is why, even now, RA patients still cannot plan their lives as
non-affected people can.
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Rheumatoid arthritis (RA) is as a chronic progressive dis-
ease and if left untreated, leads to a premature loss of joint
function. Irreversible joint damage can occur within one
year of first symptoms. Early diagnosis as well as early
treatment is therefore of paramount importance [1,2].
There has been a paradigm shift towards an early-adoption
of aggressive treatment of RA within the last decades. In-
vention of effective regimes has improved the therapeutic
possibilities dramatically. Whereas until the end of the
1990s a decrease in swollen joints and a reduction of pain
was an achievable and acceptable goal, today the overarch-
ing principle of all therapeutic efforts is to achieve a state
of remission, which can also be defined as a symptom free
status [3-5].
Remission is currently defined differently; however, pa-
tient reported outcome (PRO) scores are becoming in-
creasingly important [6-18].
The US Food and Drug administration (FDA) defined
PROs as follows: “A patient reported outcome is any re-
port of the status of a patient’s health condition that
comes directly from the patient, without interpretation of
the patient’s response by a clinician or anyone else”.
Thus, PRO variables are for instance pain, quality of life,
medical care, coping mechanisms, subjective health sta-
tus, physical activity and working ability [15].
Until now, no combined patient reported outcome
(PRO) score exists, which is generally accepted for monitor-
ing RA exclusively and which focuses on the perspective of
the patient as a primary outcome value [12,14]. Composite
indexes, primarily focusing on the opinions of physicians
are commonly applied in RA assessment [12,14].
The focus of this study was laid on the personal per-
ception of RA patients. The primary research question
of the study was: How do patients with RA who have
been treated along accepted guidelines [19,20] see the
state of their health, their joint pain and accordingly
their well-being at different points in time. Respectively,
what is the intra-subject correlation in quality of life as-
sessment when measured over different times?
Is it realistic to postulate a stable, predictable disease
status for RA patients, as it is the case in most clinical
trials? Alternatively, is the individual perception vastly
different from such a situation? Is it true that these pa-
tients are not in a position to plan mountaineering or a
hiking trip, a journey abroad or a stressful international
meeting due to fluctuations in their RA status?
We report here on the results of a survey targeting
these very questions.
Methods
To this end, a questionnaire was developed by the group of
authors in a number of meetings together with Karmasin
Motivforschung (Motivation Research) – an independentinstitute that researches communication and target groups.
The rheumatologists provided the focus and the specialist
input.
After having formulated our research questions a topic
guide akin to an interview schedule was developed by
the authors. The authors (most of them board members
of the Austrian society of rheumatology) intentionally
did not use one of the existing tools, as they did not fit
our research question, but agreed to create a new ques-
tionnaire, based on existing validated generic tools [21].
A Delphi approach including two rounds and a final
meeting was applied for consensus-building. Subse-
quently pilot interviews with volunteer participants
(eight patients) were performed, ensuring that all of the
interview questions were relevant and appropriate. The
interviews were repeated once showing that all of the
interview questions were reliable. The pilot and final
questionnaires differed only slightly in wording. No pa-
tients, who were recruited to take part in the study were
interviewed in the pilot phase.
The questionnaire which has a modular approach to dis-
ease assessment consists of demographic data, pain vari-
ables, pain relieving and intensifying factors, previous
treatment procedures, disease related disability, social fac-
tors and health related quality of life. Primarily no psycho-
metric testing was performed, as the research should
predominantly focus on the course of the disease and not
on the personality of patients with rheumatoid arthritis.
Socio-demographic details about sex, age, current place
of residence, level of education and disease duration as
well as initial clinical data were evaluated with the printed
questionnaire before the start of the telephone survey.
Disease severity was defined on 5-part scale (1=very
good, 5 =very bad) by the patient. Karmasin Motiv-
forschung was also involved in the development of the
questionnaire, namely in the setting and compilation of
questions and also gave their support regarding the
wording. The printed questionnaires (Additional file 1)
ultimately to be filled in personally (paper and pencil),
were then distributed to the physicians formerly agreed
upon. A nationwide sample was found being more rep-
resentative for this research question.
These physicians then distributed the appropriate papers
to their patients (questionnaire, information hand-out,
consent form – to be signed by both the patient and phys-
ician) during consulting hours. The physicians explained
the study to them and answered any questions. The ques-
tionnaires had to be completed by the patients at home
and be returned by mail (a stamped, addressed envelope
to Karmasin Motivforschung was provided), between the
20th of October 2010 and the 19th of April 2011. This
method of procedure was chosen on the one hand, to pre-
clude any influence of the physicians on the patients’ an-
swers and on the other, to preserve their privacy.
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Rheumatology classification criteria [22].
In the subsequent telephone interviews (Additional file 2)
performed by employees of Karmasin Motivforschung, the
patients´ feelings about their illness, their every-day coping
mechanisms and their social lives were rated.
The returned, personally answered questionnaires formed
the basis for the three telephone interviews. These ques-
tionnaires included the patients´ contact details (including
a telephone number that could be used for an interview).
All questionnaires returned before the start of the tele-
phone survey were included as baseline reference data
for use in tracking.
Three telephone interviews (CATI Computer Assisted
Telephone Interview) lasting roughly fifteen minutes each,
followed in the form of a three wave tracking study.
Baseline call: 21st February to 7th March 2011
1st wave of calls: 21st March to 11th April 2011
2nd wave of calls: 23rd May to 30th May 2011
The test patients, whose questionnaires had only been
returned after the baseline calls had begun, could only
be involved from this time onwards. It was only possible
for them to be monitored in the 1st and 2nd waves.
Ideally, the test patients were interviewed three times.
This was however dependent on their availability and
willingness to take part. The structure of the sample was
therefore not identical throughout all three component,
tracking waves.
Karmasin Motivforschung undertook data collection
without any influence exerted by the participating physi-
cians. The project was reviewed and approved by the
ethics committee of the Medical University of Graz.
For statistical analysis, telephone interview questions
were grouped into the following two categories:
Subjective health status:
The questions assigned to this category were:
 “How would you describe your current state of
health?” (Q1)
 “How would you describe your overall feeling of
well-being at the present moment?” (Q2)
 “How is your joint pain today?” (Q3)
 “How happy are you today with the general state of
your illness?” (Q4)
These questions were answered on a scale from one
(best) to five (worst).
Quality of life:
The questions assigned to this category were:
 “To what extent is the quality of your life today
influenced by the illness, rheumatoid arthritis?” (Q5) “Which ramifications does rheumatoid arthritis have
for your life today?” (Q6)
 “How are you dealing with your illness today?” (Q7)
 “Which of the following has a bearing on your
quality of life in relation to your illness, today?” (Q8)
 “Think of your own personal future in relation to
your illness. What attitude do you have to your own
future at this time?” (Q9)
Q5 was answered on a scale from one (not at all) to
five (extremely); the other four questions had multiple
answers.
Qualitative baseline characteristic data was analysed
descriptively, using counts and frequencies.
In addition to descriptive statistics, answers given at
different times (baseline, 1st wave and 2nd wave) were
compared using the Friedman test for data assessed on
an ordinal scale (mostly 1 (e.g. very good) to 5 (e.g. very
bad)). Cochran’s Q test was used for the evaluation of
data collected from dichotomous answers (i.e. yes/no).
Confidence intervals for qualitative data were obtained
using the bootstrapping method based on 10,000 replica-
tions. Two-sided p-values were calculated with a signifi-
cance level of α =0.05.
Intra-class (i.e. intra-subject in our study) correlation
coefficients (ICCs) for one-way random single measures
(type (1, 1)) between different specific times (i.e. baseline
vs. 1st wave, baseline vs. 2nd wave and 1st wave vs. 2nd
wave) were calculated for ordinal data. For dichotomous
data, Cohen’s Kappa was calculated to estimate the level
of agreement among the different points in time.
In addition, we performed subgroup analyses for sex
(men vs. women), if patients had been receiving bio-
logics or not and for disease duration (≤3 years vs. 4 to
10 years vs. ≥11 years). Single, specific measurements of
ordinal data from the groups were compared with
Mann–Whitney-U tests/Kruskal-Wallis tests. ICCs were
considered significantly different between the two strata
if the 95% confidence intervals did not overlap. Statis-
tical analyses were performed using SPSS software
(SPSS, Inc., Chicago, Illinois), version 20.
Results
Results of the questionnaire
One hundred and twenty-seven patients completed the
questionnaire. The sample includes patients from the
whole of Austria with a particular emphasis on Lower
Austria (57 patients, 45%), Upper Austria (31 patients,
24%) and Tyrol (25 patients, 20%), 14 patients (12%)
come from other provinces. These three federal prov-
inces are very similar with respect to their history and
their socio-economic status, compared to the other six
provinces in Austria, but do display minor topographical
differences, the Tyrol being more mountainous.
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compulsory education, 28 (22%) an education to certifi-
cate level and 25 (20%) education to college/university
level. 5 (4%) did not answer the question.
Size of community: 80 (63%) of the patients lived in
communities of under 5,000 inhabitants; a further 23(18%)
in communities of under 50,000 inhabitants; 21(17%) in
communities of over 50,000 inhabitants and 3 (2%) did
not answer the question.
Eleven percent of the participants are younger than 45,
35% are between 45 and 60 and 53% are 60 and older.
The first RA symptoms occurred before the age of 30 in
22% of the patients, in 15% before the age of 40, in a fur-
ther 22% before the age of 60, and in 10% after the age
of 60. Table 1 shows further demographic data and the
opinions of patients on their medical care as expressed
in their questionnaire answers.
In 18 patients (14%) rheumatoid arthritis was diag-
nosed within 3 years before study start, in 30 patients
(24%) between 4 and 10 years, and in 28 patients (22%)
disease was diagnosed more than 10 years ago. For the
remaining patients (40%) exact dates were missing and
disease duration could not be calculated.
Results of the subsequent telephone interviews
A) Subjective health status
The results are summarized in Tables 2 and 3. The
answers to all questions were quite similar every time
the calls were made and have an average rating of 2.6
to 2.9 with standard deviations ranging from 0.9 to 1.2.
Friedman test does not reveal any statistically signifi-
cant differences between the different times.
Only 12%, 10% and 9% of all patients interviewed at
baseline, first and second wave respectively, describe
their current state of health as very good and only 9%,
13% and 11% of them are free of joint pain when inter-
viewed, all three times.
Intra-subject correlation in the answers between
baseline and first wave, baseline and second wave as
well as first wave and second wave range between 0.35
and 0.48.
Overall individual subject ratings for Q1 can be seen
in Figure 1 at all three assessment times. Only 20 of 127
participants express identical ratings each time they were
monitored. In 29 of the participants, there is a difference
of two on the 5-part scale at least two of the times and
in four cases, a difference of three also at least twice for
over the complete monitoring period.
An analogue figure for Q3 can be found in Figure 2.
Here, only 14 of 127 participants display identical rat-
ings when monitored all three times. In 40 of the par-
ticipants, there is a difference of two on the 5-partscale, at least twice and in four cases a difference of three
also at least twice over the whole monitoring period.
Subgroup analyses were performed for men and
women, for patients currently treated with or without bi-
ologics and for patients with a disease duration ≤3 years,
4 to 10 years, and ≥11 years. Results are displayed in
Table 4. Neither mean values nor ICCs differed signifi-
cantly between categories in any subgroup. The propor-
tion of patients with identical ratings overall and of
those whose ratings differed by at least two, were com-
parable in all subgroups.
B) Quality of life
The results are summarized in Tables 2 and 3. For Q5
and some elements of Q6, Q7 and Q8 statistically sig-
nificant (p-value < 0.05), differences in answers at differ-
ent times could be detected.
The illness encroaches upon the quality of life, average
rating answers to Q5 being 3.2 ± 1.2, 2.8 ± 1.2 and 2.7 ±
1.2 at the three different times. The answers of only 12
of 129 participants (9.3%) were the same all three times.
In 42 of the participants (32.6%), there was a difference
of two on the 5-part scale at least twice and in ten cases
(7.8%) a difference of three at least twice over the entire
monitoring period. Intra-subject correlations between
single times range from between 0.41 to 0.56.
The main implications for RA patients as evaluated
with Q6 are stress due to pain, and interference with
their daily lives, which is of relevance for more than half
of the patients.
In dealing with the illness (Q7), medication and the inte-
gration of the illness into day-to-day life are most import-
ant: 82% to 94% of all patients handle the disease this way.
No levels of agreement on single elements of Q6 and
Q7 reaching a value greater than 0.5, but there is some
low level agreement. For example the elements “The ill-
ness has little or no influence on my life”, ”Medication
makes handling of the illness easier” and “I adopted a
positive attitude towards the illness” reached levels of
agreements of under 0.15.
Only a small proportion of all patients (5%, 9% and
12% at each interview wave, respectively) are generally
pessimistic regarding their own future (Q9), while 55%,
47% and 51% are generally optimistic. The rest has a
neutral view. Intra-subject correlation between the dif-
ferent times range from 0.31 to 0.55 for this question.
Subgroup analysis of Q5 for men and women and for
patients receiving or not receiving biologics showed simi-
lar results on all levels with no relevant deviation (Table 4).
For the subgroup with a disease duration ≤3 years ICCs
were considerably smaller than in patients with longer
disease duration, but results were not statistically
significant.
Table 1 Overall patient information and patients’ attitude
towards medical care
Characteristic Number (% of total)






Younger than 45 years 14 (11%)
45 to 60 years 45 (35%)
Older than 60 67 (53%)
No answer 1 (1%)
First occurrence of RA symptoms
Before the age of 30 28 (22%)
Between the age of 30 and 40 19 (15%)
Between the age of 40 and 50 28 (22%)
Between the age of 50 and 60 38 (30%)
After the age of 60 13 (10%)
No answer 1 (1%)
Disease duration1
Median (IQR) [years] 8.5 (4–13)
≤3 years 18 (14%)
4 to 10 years 30 (24%)
≥11 years 28 (22%)





No answer 3 (2%)
Medical care
Satisfaction with information received
from physician during diagnostic process
Very satisfied 65 (51%)
Satisfied 30 (24%)
Neutral 17 (13%)
Not particularly happy 9 (7%)
Completely dissatisfied 4 (3%)
No answer 2 (2%)
Patient was included in therapeutic






Table 1 Overall patient information and patients’ attitude
towards medical care (Continued)
Sulphasalazine 7 (6%)
Chloroquine/hydrochloroquine 4 (3%)
Concomitant glucocorticoids 56 (44%)
Biologics 36 (28%)
Alternative or complementary remedies 17 (13%)
IQR – interquartile range.
1Disease duration could only be calculated if not only the categories, but also
the exact age of diagnosis of disease and current age were provided. Since
many patients did not provide this information in the questionnaire, disease
duration could not be computed for 51 patients.
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The results derived from the tracking system demon-
strate those issues generally seen as cornerstones of the
clinical picture, independently of the selected times of
monitoring. We were concerned with highlighting those
dimensions of the illness that occur with regularity and
defining patients´ handling of their disease.
The participating patients can be regarded as an aver-
age RA population, expressing acceptable mean ratings
for satisfaction with disease status, pain, quality of life
and general health.
The disease has a bearing on the quality of life, which
each individual patient experiences differently. Over
time, patients necessarily come to terms with this situ-
ation, which in turn lessens the relevance of the health
impairment.
The illness has a significant influence on the life of an
RA patient, in particular the symptom of pain. The results
are very much in line with a study by Hewlett et al. [23].
In 2011 a EULAR initiative devised a Rheumatoid Arth-
ritis Impact of Disease (RAID) score; a patient derived
composite measure of the impact of RA. Parameters of
major importance for the patients were pain, followed by
physical limitations, fatigue, emotional well-being, and
sleep as well as coping mechanisms [24-26]. Again, our re-
sults support these findings.
One fundamental conclusion from our study, and a
strength of the research, is that the individual patient’s
self-appraisal of their disease is quite mutable. Although
means and percentages show markedly uniform patterns
and acceptable results for the observation period, intra-
subject correlation and level of agreement at different
times, disappointingly is quite modest in general: High
correlation (ICC/kappa ≥ 0.5) was hardly detected in any
answers. Most correlation was only moderate (0.25 – 0.5)
or even weak (0–0.25). The pattern was similar in all sub-
groups analysed.
These conclusions are valid for all questions in the two
categories (subjective health status and quality of life).
Specifically, the answers to the question on the current
state of health of participants are consistent with this
Table 2 Summary of answers to the questionnaire at the three different time-points
Baseline (N = 110) 1st wave (N = 109) 2nd wave (N = 113) p-value
Mean ± SD or pct.
(95% CI)
Mean ± SD or pct.
(95% CI)
Mean ± SD or pct.
(95% CI)
Category: subjective health status
How would you describe your current state of health? 2.6 ± 0.9 2.8 ± 1.1 2.8 ± 1.0 0.2031
How would you describe your overall feeling of well-being at the
present moment?
2.7 ± 1.1 2.7 ± 1.2 2.6 ± 1.0 0.6061
How is your joint pain today? 2.9 ± 1.1 2.8 ± 1.1 2.9 ± 1.1 0.8871
How happy are you today with the general state of your illness? 2.7 ± 1.2 2.6 ± 1.2 2.8 ± 1.2 0.4071
Category: quality of life
To what extent is the quality of your life today influenced by the illness,
rheumatoid arthritis?
3.2 ± 1.2 2.8 ± 1.2 2.7 ± 1.2 <0.0011
Which ramifications does rheumatoid arthritis have for your life today?
(more than one answer possible)
The pain stresses me 70.0% (60.9-78.2) 66.1% (56.9-75.2) 67.3% (58.4-76.1) 0.6762
The pain affects my daily life 70.0% (61.8-78.2) 49.5% (40.4-58.7) 46.9% (38.1-55.8) <0.0012
The illness has psychological repercussions 51.8% (42.7-60.9) 42.2% (33.0-51.4) 42.5% (33.6-51.3) 0.1232
In spite of my illness, full performance is expected of me 26.4% (18.2-34.5) 32.1% (23.9-41.3) 25.7% (17.7-33.6) 0.2752
The illness has little or no influence on my life 25.5% (17.3-33.6) 44.0% (34.9-53.2) 36.3% (27.4-45.1) 0.0042
The illness has had a negative influence on my social status 22.7% (15.5-30.9) 20.2% (12.8-27.5) 26.5% (18.6-34.5) 0.5662
How do you deal with your illness today? (more than one answer possible)
Medication makes handling of the illness easier 90.0% (83.6-95.5) 93.6% (89.0-97.2) 83.2% (76.1-89.4) 0.0392
The illness is simply part of everyday life i.e. I have learned to
come to terms with it
81.8% (74.5-89.1) 86.2% (79.8-92.7) 83.2% (76.1-89.4) 0.8302
I adopted a positive attitude towards the illness 33.6% (25.5-42.7) 63.3% (54.1-72.5) 52.2% (43.4-61.1) <0.0012
The illness is just a burden 17.3% (10.0-24.5) 31.2% (22.9-40.4) 28.3% (20.4-36.3) 0.0062
Which of the following has a bearing on your quality of life in relation
to your illness, today? (more than one answer possible)
Independence, i.e. doing things that I want to do 82.7% (75.5-89.1) 82.6% (75.2-89.0) 80.5% (72.6-87.6) 0.7052
Being active, e.g. sports or going places and doing things 74.5% (66.4-82.7) 76.1% (67.9-83.5) 80.5% (73.5-87.6) 0.8092
Social activity, e.g. meeting friends 72.7% (64.5-80.9) 78.9% (71.6-86.2) 83.2% (76.1-89.4) 0.2002
Good physical well-being, e.g. being pain-free and mobile 61.8% (52.7-70.9) 82.6% (75.2-89.0) 78.8% (71.7-85.8) 0.0012
Other 2.7% (0.0-6.4) 3.7% (0.9-7.3) 3.5% (0.9-7.1) 1.0002
Think of your own personal future in relation to your illness. What
attitude do you have to your own future at this time? (single choice)
Generally optimistic 54.5% (45.5-63.6) 46.6% (36.9-56.3) 52.4% (42.7-62.1) 0.1791
Neutral 40.0% (30.9-49.1) 43.7% (34.0-53.4) 35.0 (26.2-44.7)%
Generally pessimistic 5.5% (1.8-10.0) 9.7% (3.9-15.5) 12.6% (6.8-19.4)
N – number of answered questionnaires; SD – standard deviation; CI – confidence interval; percentages (pct.) are based on N; CIs were obtained by bootstrapping
method based on 10000 replications; NC – not captured.
1p-value of Friedman test; 2p-value of Cochran’s Q test.
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telephone interviews are quite similar and at 2.6, 2.8
and 2.8 and show no statistically significant differences.
Nevertheless, intra-subject correlations only range from
0.38 to 0.50 – which is only a modest relationship but
still higher than for many other questions. A very simi-
lar picture could be seen for joint pain. The number ofparticipants whose answers differed by at least two at
different times, was surprisingly high.
We only can speculate about the factors causing the sig-
nificant differences between the three waves detected for
the answers to the question to what extent the partici-
pant’s quality of life is influenced by the illness at that
moment, as well as some sub-elements of the multiple







Category: subjective health status
How would you describe your current state of health? 0.371 0.481 0.471
How would you describe your overall feeling of well-being at the present moment? 0.391 0.391 0.401
How is your joint pain today? 0.481 0.371 0.401
How happy are you today with the general state of your illness? 0.351 0.401 0.461
Category: quality of life
To what extent is the quality of your life today influenced by the illness, rheumatoid arthritis? 0.471 0.411 0.561
Which ramifications does rheumatoid arthritis have for your life today (more than one answer possible)?
The pain stresses me 0.452 0.372 0.392
The pain affects my daily life 0.482 0.192 0.292
The illness has psychological repercussions 0.312 0.422 0.332
In spite of my illness, full performance is expected of me 0.412 0.392 0.352
The illness has little or no influence on my life 0.132 0.122 0.372
The illness has had a negative influence on my social status 0.282 0.252 0.262
How are you dealing with your illness today (more than one answer possible)?
Medication makes handling of the illness easier 0.192 0.232 0.082
The illness is simply part of everyday life i.e. I have learned to come to terms with it 0.162 0.362 0.252
I adopted a positive attitude towards the illness 0.232 0.082 0.112
The illness is just a burden 0.322 0.262 0.372
Which of the following has a bearing on your quality of life in relation to your illness, today
(more than one answer possible)?
Independence, i.e. doing things that I want to do 0.122 −0.042 0.102
Being active, e.g. sports or going places and doing things 0.112 0.192 0.052
Social activity, e.g. meeting friends 0.142 0.112 0.142
Good physical well-being, e.g. being pain-free and mobile 0.032 −0.042 0.142
Other 0.562 −0.032 −0.042
Think of your own personal future in relation to your illness. What attitude do you have to your own future
at this time? (single choice)
0.551 0.311 0.531
1Intraclass correlation coefficient (ICC) for one-way random single measures; 2Cohen’s Kappa.
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long disease duration such differences were not expected.
Aside from the fact that disease activity fluctuations could
give the reason for such differences, a growing indifference
to the questionnaire and impatience with the telephone
calls could be - at least in part - responsible for this
phenomenon. Although no differences registered at differ-
ent times were observed for most of the questions, this is
a point, which remains open and is worth further explor-
ation in the future.
Another shortcoming of the study lies in the lack of ap-
plication of a widely used patient reported outcome meas-
ure used in RA. For example, the Routine Assessment of
Patient Index Data 3 (RAPID3) [16], the self-administered,
Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5)
[27], the Health Assessment Questionnaire (HAQ) [28] orthe Rheumatoid Arthritis Quality of Life (RAQoL) ques-
tionnaire [29], were not captured, but this was to ensure
to exert no influence upon our patients. We also did not
calculate disease activity like Disease Activity Score 28
(DAS 28) [30] or Clinical disease activity index (CDAI)
[31], as a decision was reached not to carry out routine
consultations with a rheumatologist during the two month
observation time, in order not to influence the telephone
Interviews. Therefore, we were not able to compare our
newly developed questionnaire with well-established
scores or measurements and could not perform a valid-
ation procedure. No validation data of the questionnaire
in RA is a limitation. We adapted our questionnaire to a
telephone survey in the form of three-wave tracking and
mostly used numerical rating scales for items like pain,
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Figure 1 “How would you describe your current state of health?” (Individual ratings).
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been suited to the research question.
Individual assessment of health levels, well-being, joint
pain and the quality of life is quite unsteady, even withina time frame of about two months. Due to disease fluc-
tuation, a prediction of health levels, personal well-being
and joint pain as well as the quality of life for the indi-
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Figure 2 “How is your joint pain today?” (Individual ratings).
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tient; even nowadays, the planning of activities for the
nearest future can create difficulties for them and theirenvironment, irrespective from modern diagnostic tech-
niques as well as from the availability of adequate therapy.
Far more individualised treatment schedules adapted to
Table 4 Subgroup analyses for sex and treatment with biologics




IC C 1st wave
vs. 2nd waveMean ± SD Mean ± SD Mean ± SD
Category: subjective health status
How would you describe your current state of health?
Men 2.5 ± 0.8 2.6 ± 1.1 2.7 ± 1.1 0.29 0.44 0.56
Women 2.6 ± 0.9 2.8 ± 1.1 2.8 ± 1.0 0.39 0.49 0.44
Biologics as current medication 2.6 ± 0.9 2.7 ± 1.1 2.7 ± 1.1 0.51 0.57 0.54
No biologics as current medication 2.6 ± 0.9 2.9 ± 1.1 2.8 ± 1.0 0.30 0.41 0.43
Disease duration ≤3 years 2.8 ± 0.8 2.8 ± 1.1 2.7 ± 0.8 0.45 0.50 0.50
Disease duration 4 to 10 years 2.7 ± 0.9 2.9 ± 1.2 3.0 ± 1.2 0.57 0.47 0.58
Disease duration ≥11 years 2.4 ± 1.0 2.8 ± 1.1 2.9 ± 0.9 0.41 0.60 0.32
How would you describe your overall feeling
of well-being at the present moment?
Men 2.7 ± 1.0 2.6 ± 1.2 2.6 ± 0.9 0.63 0.32 0.48
Women 2.7 ± 1.1 2.7 ± 1.2 2.7 ± 1.1 0.35 0.40 0.39
Biologics as current medication 2.5 ± 1.0 2.6 ± 1.2 2.7 ± 1.2 0.32 0.29 0.38
No biologics as current medication 2.8 ± 1.2 2.7 ± 1.1 2.6 ± 0.9 0.42 0.45 0.42
Disease duration ≤3 years 2.8 ± 1.1 2.5 ± 1.1 2.6 ± 0.9 0.18 0.47 0.46
Disease duration 4 to 10 years 2.8 ± 0.9 2.8 ± 1.2 2.7 ± 1.0 0.57 0.53 0.29
Disease duration ≥11 years 2.6 ± 1.3 2.7 ± 1.1 2.8 ± 1.1 0.59 0.34 0.28
How is your joint pain today?
Men 3.0 ± 1.0 2.7 ± 1.0 2.9 ± 1.2 0.28 0.20 0.25
Women 2.9 ± 1.2 2.8 ± 1.1 2.8 ± 1.1 0.52 0.42 0.42
Biologics as current medication 2.7 ± 1.0 2.8 ± 1.2 2.9 ± 1.2 0.69 0.44 0.57
No biologics as current medication 3.0 ± 1.2 2.8 ± 1.1 2.9 ± 1.1 0.39 0.34 0.31
Disease duration ≤3 years 2.9 ± 1.2 2.6 ± 1.3 2.8 ± 1.2 0.25 0.23 0.64
Disease duration 4 to 10 years 2.7 ± 1.0 3.0 ± 1.2 3.0 ± 1.1 0.60 0.50 0.45
Disease duration ≥11 years 2.9 ± 1.3 2.7 ± 1.2 3.0 ± 1.0 0.48 0.20 0.22
How happy are you today with the general state of your illness?
Men 2.7 ± 1.2 2.6 ± 1.3 2.7 ± 1.4 0.24 0.46 0.65
Women 2.7 ± 1.2 2.7 ± 1.1 2.8 ± 1.2 0.38 0.38 0.41
Biologics as current medication 2.4 ± 1.0 2.7 ± 1.2 2.7 ± 1.3 0.52 0.41 0.48
No biologics as current medication 2.8 ± 1.3 2.6 ± 1.2 2.8 ± 1.2 0.28 0.39 0.46
Disease duration ≤3 years 2.6 ± 1.4 2.5 ± 1.2 2.5 ± 1.3 0.46 0.16 0.39
Disease duration 4 to 10 years 2.5 ± 1.0 2.9 ± 1.3 2.8 ± 1.2 0.47 0.47 0.73
Disease duration ≥11 years 2.9 ± 1.4 2.6 ± 1.1 2.9 ± 1.3 0.25 0.51 0.24
Category: quality of life
To what extent is the quality of your life today influenced by
the illness, rheumatoid arthritis?
Men 3.0 ± 1.3 2.8 ± 1.5 2.6 ± 1.2 0.33 0.39 0.58
Women 3.2 ± 1.2 2.8 ± 1.2 2.6 ± 1.2 0.51 0.42 0.56
Biologics as current medication 3.1 ± 1.2 2.6 ± 1.2 2.7 ± 1.3 0.39 0.37 0.64
No biologics as current medication 3.2 ± 1.2 2.8 ± 1.3 2.7 ± 1.1 0.51 0.44 0.52
Disease duration ≤3 years 3.1 ± 1.1 2.3 ± 1.1 2.5 ± 1.0 0.03 0.07 0.21
Disease duration 4 to 10 years 3.1 ± 1.0 3.0 ± 1.3 2.8 ± 1.3 0.52 0.49 0.56
Disease duration ≥11 years 3.2 ± 1.3 2.6 ± 1.2 2.7 ± 1.2 0.48 0.53 0.62
SD – standard deviation; ICC - Intraclass correlation coefficient for one-way random single measures.
No statistically significant differences between men and women, between use of biologics and no biologics, and between disease duration subgroups were observed.
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ously also implies high patient involvement into thera-
peutic decision-making.
Conclusions
There is consensus amongst RA patients on some over-
all key statements with respect to the course of the dis-
ease. On an individual level, however, most patients do
not achieve a truly steady state of disease even within
the short time-frame of two months and therefore they
are limited in planning their near future. The individual
course of disease in RA is not a simple linear linking of
two observations, as clinical trial charts often give cause
to believe. High fluctuation between two observations is
the rule rather than the exception.
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